Journal of Vaccines & Vaccination

Why whooping cough is back and what vaccines need to be developed to counter it: Next generation pertussis vaccines and relevance of adenylate cyclase toxin-hemolysin

7^th Middle East - Global Summit and Expo on Vaccines & Vaccination

September 28-29, 2015 Dubai, UAE

Peter Sebo

Academy of Sciences of the Czech Republic, Czech Republic

Posters-Accepted Abstracts: J Vaccines Vaccin

Abstract:

The adenylate cyclase toxin-hemolysin (ACT, AC-Hly or CyaA) is a key virulence factor of Bordetella pertussis. It targets bactericidal activities of phagocytes such as oxidative burst and complement or antibody-mediated opsonophagocytic killing of bacteria. Through cAMP signaling, CyaA skews also TLR-triggered maturation of dendritic cells inhibiting proinflammatory IL-12 and TNF-α secretion and enhancing IL-10 production and Treg expansion likely hampering also induction of adaptive immune responses to Bordetella infections. Non-enzymatic CyaA toxoid is a potent protective antigen and adjuvant that boosts immunogenicity of co-administered B. pertussis antigens and improves potency of acellular pertussis (aP) vaccines in mice. This makes CyaA to a prime antigen candidate for inclusion into a next generation of aP vaccines. Moreover, recombinant CyaA toxoids were recently shown to be safe in humans in frame of phase-I clinical evaluation of a CyaA-based immunotherapeutic vaccine that induces Th1-polarized CD8+ cytotoxic T-lymphocyte response targeting cervical tumors. In the last part of the lecture, the need for and ways of making a safer next generation whole cell pertussis vaccine (wP) for most developed countries will be outlined.

Biography :

Email: sebo@biomed.cas.cz